Celladon Corporation is a clinical-stage biotechnology company that specializes in developing cardiovascular gene therapy and calcium dysregulation. Its lead product candidate, MYDICAR, utilizes genetic enzyme replacement therapy to address deficiencies in the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme that contribute to heart failure. MYDICAR is intended for patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as for those with pulmonary arterial hypertension and arteriovenous fistula maturation failure.